Exclusive Summary

• - Patent barriers largely expired; IV generics already in US/EU with more markets opening for entry.
• - Target population spans AML/MDS induction therapy and allogeneic HSCT with GVHD, totaling roughly 100,000–200,000 prophylaxis candidates globally per year.
• - International guidelines (IDSA, ECIL) endorse posaconazole as first-line prophylaxis in high-risk hematology; IV formulation is key when oral absorption is unreliable.
• - Competition exists in US/EU (several IV generics), but supply remains limited across many LMICs—stable supply and strong distribution are clear differentiators.
• - Compared with originator, generic IV therapy can cut daily costs by 30–60%, saving thousands to tens of thousands per full course in hospital budgets.